USD 5.4 Million to advance Prevision Medicine’s functional precision oncology platform
Prevision Medicine closed a seed round of USD 5.4 million, led by Swiss-based ACE Ventures, to accelerate the commercialization of its single‑cell functional precision oncology platform for hematological malignancies and solid tumors. The platform evaluates living tumor‑derived cells against a treatment library, providing rapid, actionable reports that guide personalized therapy. The funding will support regulatory approvals, reimbursement coverage, and operational expansion across Europe.
Prevision Medicine closed a seed round of USD 5.4 million, led by Swiss-based ACE Ventures, to accelerate the commercialization of its single‑cell functional precision oncology platform for hematological malignancies and solid tumors. The platform evaluates living tumor‑derived cells against a treatment library, providing rapid, actionable reports that guide personalized therapy. The funding will support regulatory approvals, reimbursement coverage, and operational expansion across Europe.
The investment underscores Switzerland’s growing role in AI‑driven precision medicine, with a Zurich‑based company leveraging functional testing to improve cancer care.
Original source record. Open the original record to verify the underlying announcement.